A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Merck Sharp & Dohme LLC
Eli Lilly and Company
Baylor College of Medicine
Bayer
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
GlaxoSmithKline
Pfizer